Paige, a NYC-based AI-powered digital diagnostics company, raised $100m in Series C funding.
The round was led by Casdin Capital and Johnson & Johnson Innovation – JJDC, Inc. (JJDC), the strategic venture capital arm of Johnson & Johnson. Existing investors and other funds are also participating in the round.
The company intends to use the funds to accelerate development of AI-based clinical applications, biomarkers and diagnostics, invest in sales and marketing efforts to scale product adoption by hospitals and labs, and build out its engineering and commercial teams with plans to hire about 70 new employees in 2021.
Founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from Memorial Sloan Kettering Cancer Center (MSK) and led by Leo Grady, Ph.D., Chief Executive Officer, Paige builds computational pathology products designed so patients and their care teams can make more informed treatment decisions. The company’s products – which received FDA breakthrough designation – deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. for computational pathology products.